Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy

Maire, CL, Ramkissoon, S, Hayashi, M, Haidar, S, Ramkissoon, L, Ditomaso, E and Ligon, KL (2014) Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells. pp. 313-326.


Therapeutic modulation of phosphatidylinositol 3-kinase (PI3K)/PTEN signaling is currently being explored for multiple neurological indications including brain tumors and seizure disorders associated with cortical malformations. The effects of PI3K/PTEN signaling are highly cell context dependent but the function of this pathway in specific subsets of neural stem/progenitor cells generating oligodendroglial lineage cells has not been fully studied. To address this, we created Olig2-cre:Ptenfl/ fl mice that showed a unique pattern of Pten loss and PI3K activation in Olig2-lineage cells. Olig2-cre:Ptenfl/fl animals progressively developed central nervous system white matter hypermyelination by 3 weeks of age leading to later onset leukodystrophy, chronic neurodegeneration, and death by 9 months. In contrast, during immediate postnatal development, oligodendroglia were unaffected but abnormal and accelerated differentiation of lateral subventricular zone stem cells produced calretinin-positive interneuron dysplasia. Neural stem cells isolated from Olig2-cre:Ptenfl/fl mice also exhibited accelerated differentiation and proliferation into calretinin-positive interneurons and oligodendrocytes indicating such effects are cell autonomous. Opposition of the pathway by treatment of human primary neural progenitor cells (NPCs) with the PI3K inhibitor, NVP-BKM120, blocked in vitro differentiation of neurons and oligodendroglia indicating PI3K/PTEN effects on NPCs can be bidirectional. In summary, our results suggest Pten is a developmental rheostat regulating interneuron and oligodendroglial differentiation and support testing of PI3K modulating drugs as treatment for developmental and myelination disorders. However, such agents may need to be administered at ages that minimize potential effects on early stem/progenitor cell development. AlphaMed Press 2013

Item Type: Article
Additional Information: NIBR author: DiTomaso, E institute: NIBR contributor address: (Maire, Ramkissoon, Hayashi, Haidar, Ramkissoon, Ligon) Department of Pathology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 450 Brookline Avenue JFB 215B, Boston, MA 02215, United States (Ramkissoon, Ligon) Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital and Children's Hospital Boston, Boston, MA, United States (Ditomaso) Novartis Institutes for Biomedical Research, Basel, Switzerland (Ramkissoon, Ligon) Department of Pathology, Harvard Medical School, Boston, MA, United States
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12


Email Alerts

Register with OAK to receive email alerts for saved searches.